BuzzSparks.org

Amgen


biotechnology company

Amgen Inc.. The Group’s principal activities are to discover, develop, manufacture and market human therapeutics based on advances in cellular and molecular biology. It markets human therapeutic products in the areas of hematology, oncology...

Founded in 1985
Homepage:
Total money raised: $175.5M

HQ

91320-1799 One Amgen Center Drive

Thousand Oaks
Thousand Oaks
USA CA

Phone: +1 805-447-1000

Updated on Sep 13, 2013
Amgen at CrunchBase
Robert A. Bradway Chairman and Chief Executive Officer
Michael Severino SVP, Global Development and Corporate Chief Medical Officer
Cynthia M. Patton SVP and Chief Compliance Officer
Diana L. McKenzie SVP and CIO
Jonathan M. Peacock EVP and CFO
Brian M. McNamee SVP, Human Resources
Anthony C. Hooper EVP, Global Commercial Operations
Sean E. Harper EVP, Research and Development
Suzanne Blaug SVP, Global Marketing and Commercial Development
Madhavan Balachandran EVP, Operations
Carol Gallagher
Paul R. Eisenberg Senior Vice-President
Raymond C. Jordan SVP, Corporate Affairs
David J. Scott SVP, General Counsel and Secretary
Frank Biondi Board of Director
Vance D. Coffman Board of Director
Rebecca M. Henderson Board of Director
Tyler Jacks Board of Director
Judith C. Pelham Board of Director
Leroy Hood
Victoria H. Blatter SVP
Rolf K. Hoffmann SVP, U.S. Commercial Operations
Joshua J. Ofman SVP, Global Value and Access
David Baltimore Board of Director
François de Carbonnel Board of Director
Robert A. Eckert Board of Director
Frank C. Herringer Board of Director
Gilbert S. Omenn Board of Director
Ronald D. Sugar Board of Director
Past
Lee Hood Co-Founder
Beth Seidenberg Vice President, Global Development, and Chief Medical Officer
Lowell Sears Senior Vice President & CFO
Thomas Daniel Vice President
Jin-Long Chen Vice President of Research
Philip Astley-Sparke VP / General Manager
David R. Parkinson VP, Oncology Clinical Development
Larry Bell Vice President, Global Head of Worldwide Regulatory Affairs
David L. Lacey SVP, Discovery Research
Alessandra Cesano VP Clinical Development Oncology
Mooky Desai Technology Consultant
Anne Dixon
Heather Franklin Sr. Research Operations Program Manager
Neil Hughes International Franchise Head, Bone & New Products &Marketing Exec Director
Parker Conrad Product Manager
Janis Naeve Managing Director, Amgen Ventures
Dr. Gordon Ng Scientific Director
Rick Stead Medical Director
Dennis Hom Executive Director, Corporate Development
Jim Blair Board Member
Lawrence Blatt Head of Interferon Research, Development Team Leader
Ted Snelgrove Marketing Manager
Jon Voss Manager of Validation
Aron Knickerbocker Senior Manager, Corporate Development
Hui Tian Scientific Director in the Metabolic Disorders Therapeutic Area
Marc Learned Director of Research in Metabolic Disorders
Tim Hoey Director, Biology Department (San Francisco)
Jim Haughwout
Joe Sandoval Business Planning Analyst
Stephen Gracon Senior Director, Regulatory Affairs
Sai Ram Therapeutic Area Nephrology
John Hollister Director, Global Marketing Oncology
Hal Saad Six Sigma Project Lead
Donna Matuizek Bioservices Manager
Bart Henderson Marketing Manager - Neupogen
Leping Li Scientific Director
John Moriarty Executive Director & Associate General Counsel
Lyndal Hesterberg Manager, Diagnostics
Tao Liu Sales and Marketing
MarySusan Howard Senior Counsel, IP and litigation
Luis Bayol Director of Operations
Alex DePaoli Director
Michael Mulkerrin Leadership Positions
Melissa Morandi Quality Assurance

October, 2013

Amgen invested $4.1M in Opsona as a Series C round

August, 2013

Amgen acquired Onyx Pharmaceuticals for $10.5B

Amgen Said to Be Near Deal to Buy Onyx for $10.5 Billion    dealbook.nytimes.com

June, 2013

Amgen Invests $25 Million to Expand Cytokinetics Agreement    burrillreport.com

April, 2013

Amgen invested $44.6M in Opsona as a Series C round

March, 2013

Amgen invested $8M in Theraclone Sciences as a Series B round

May, 2012

Amgen invested $10M in Gamida Cell as a Series E round

Amgen invested $16.5M in Sutro Biopharma as a Series C round

April, 2012

Amgen invested $20M in Miragen Therapeutics as a Series B round

Amgen acquired KAI Pharmaceuticals for $315M

UPDATED: Amgen snags KAI Pharma's CKD program in $315M buyout    fiercebiotech.com

March, 2012

Amgen raised $175.5M in partial round

SEC    sec.gov

January, 2012

Amgen acquired Micromet for $1.2M

Amgen to Acquire Micromet    amgen.com

August, 2011

Amgen invested $30M in Ardelyx as a Series B round

Amgen invested $2.1M in Oncofactor Corporation as a Series A round

January, 2011

Amgen acquired BioVex for $1B

BioVex to be acquired by Amgen for up to $1 billion    masshightech.com

Amgen, has reached agreement to acquire BioVex Group Inc. for what could total $1 billion

BioVex to be acquired by Amgen for up to $1 billion    masshightech.com

Amgen invested $4.4M in Acylin Therapeutics as a Series A round

November, 2010

Amgen invested $36.5M in Sutro Biopharma as a Series C round

Amgen pays Nektar $50M for polymer    fiercebiotech.com

September, 2010

Amgen invested $3.2M in DecImmune Therapeutics as unattributed round

August, 2010

Amgen invested $32M in TetraLogic Pharmaceuticals as a Series C round

June, 2010

Amgen invested $40M in Calistoga Pharmaceuticals as a Series C round

March, 2010

Amgen invested $1.5M in Theraclone Sciences as unattributed round

November, 2009

Amgen invested $7.5M in Trinity Biosystems as unattributed round

October, 2009

Amgen invested $32M in Epizyme as a Series B round

June, 2009

Amgen invested $4M in Miragen Therapeutics as a Series B round

May, 2009

Amgen invested $30M in Calistoga Pharmaceuticals as a Series B round

October, 2008

Amgen acquired Avidia for $380M

Amgen to buy inflammation drug co. Avidia for up to $380M    deals.venturebeat.com

August, 2008

Amgen invested $18.5M in InteKrin as a Series C round

October, 2007

Amgen invested $30M in Allozyne as a Series B round

June, 2007

Amgen invested $15.8M in Argolyn Bioscience as a Series A round

Amgen acquired Ilypsa for $420M

Amgen buys kidney-disease biotech Ilypsa for $420M    venturebeat.com

March, 2007

Amgen invested $21M in Calistoga Pharmaceuticals as a Series A round

July, 2006

Amgen invested $21M in Trinity Biosystems as a Series B round

June, 2006

Amgen invested $55M in VLST Corporation as a Series B round

May, 2006

Amgen invested $20M in Viron Therapeutics as a Series A round

Amgen invested $43.8M in Avidia as a Series C round

December, 2005

Amgen invested $3.5M in Allozyne as a Series A round

November, 2005

Amgen invested $26.6M in PTC Therapeutics as unattributed round

May, 2005

Amgen invested $28.5M in Avidia as a Series B round

1985

Amgen was founded in 1985

January, 1983

Amgen IPO
Stock symbol: NASDAQ:AMGN